June 5, 2014 — AstraZeneca and McKesson Corp. have been hit with a lawsuit filed by a group of twelve people who allege that Crestor (rosuvastatin), a popular cholesterol-lowering statin, caused them to develop type-2 diabetes.
The lawsuit was filed by Gloria Hererra, a resident of California, in Superior Court. However, this week it was transferred to federal court in the Central District of California. The other members of lawsuit are residents of Alabama, Arkansas, Georgia, Minnesota, North Carolina, Ohio, and Texas.
All of the plaintiffs accuse AstraZeneca and McKesson of downplaying information linking Crestor and diabetes despite knowledge of the risk.
According to the complaint (PDF):
“Defendants negligently, recklessly, and wantonly failed to warn plaintiffs, plaintiffs’ physicians and the general public, of the risks associated with Crestor. Defendants failed to do so even after various studies, including their own, showed that there were problems concerning the risks of cardiomyopathy, myocardial infarctions, sudden cardiac death, rhabdomyolysis (muscle deterioration), kidney damage, and diabetes.”
In 2012, the U.S. Food and Drug Administration (FDA) issued a Safety Communication and required updates on the label for all statins to warn about increases in blood-sugar levels and type-2 diabetes. They cited the JUPITER clinical trial, which linked Crestor to 27% more reports of diabetes than a placebo.
Type-2 diabetes is a chronic medical condition that occurs when the body cannot properly regulate blood-sugar levels because cells are desensitized to insulin, a hormone that tells cells to absorb sugar from the bloodstream. People with diabetes are at higher risk of many serious health problems, including heart disease, neuropathy, eye problems, and more.